GSWM
CUE icon

Golden State Wealth Management’s Cue Biopharma CUE Stock Holding History

Golden State Wealth Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08K Sell
66
-1
-1% -$23 ﹤0.01% 1388
2026
Q1 		$460 Hold
67
– – ﹤0.01% 1521
2025
Q4 		$611 Hold
67
– – ﹤0.01% 1576
2025
Q3 		$1.44K Hold
67
– – ﹤0.01% 1449
2025
Q2 		$1.36K Hold
67
– – ﹤0.01% 1403
2025
Q1 		$1.82K Hold
67
– – ﹤0.01% 1335
2024
Q4 		$2.18K Buy
+67
New +$2.52K ﹤0.01% 1245

Other funds holding CUE

RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Golden State Wealth Management's CUE Position: Q2 2026 in Review

Golden State Wealth Management reduced its Cue Biopharma (CUE) stake by 1.5% in Q2 2026, selling an estimated $23 and leaving 66 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1388.

Golden State Wealth Management first reported a position in CUE in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.18K in Q4 2024. 8 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Golden State Wealth Management held 66 shares of Cue Biopharma worth $2.08K as of Q2 2026.
  • Golden State Wealth Management sold 1 Cue Biopharma share in Q2 2026, an estimated $23.
  • Cue Biopharma made up ﹤0.01% of Golden State Wealth Management's portfolio in Q2 2026, its #1388 holding.
  • Golden State Wealth Management first reported a position in Cue Biopharma in Q4 2024 and has held it in 7 quarters since.
  • Golden State Wealth Management's Cue Biopharma position peaked at $2.18K in Q4 2024.
  • 8 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.